Literature DB >> 6094954

The complete nucleotide sequence of the influenza virus neuraminidase gene of A/NJ/8/76 strain and its evolution by segmental duplication and deletion.

T Miki, Y Nishida, H Hisajima, T Miyata, Y Kumahara, K Nerome, A Oya, T Fukui, E Ohtsuka, M Ikehara.   

Abstract

The neuraminidase (NA) gene from A/New Jersey (NJ)/8/76 (H1N1, formerly Hsw1 N1) strain isolated in 1976 was cloned into pBR322 and its complete nucleotide sequence was determined. The NJ8 NA gene is 1458 nucleotides long and the sequence predicted the primary structure of the NA molecule comprising of 469 amino acids with a molecular weight of 51,628. Comparison with other NA sequences of the N1 subtype strains which were isolated in 1933-1934 identified the highly variable regions at the amino-terminal stalk region and the carboxy-terminal regions. Potential glycosylation sites encoded by a 15 base-pair unit sequence are arrayed tandemly at the stalk regions. The lengths of stalk regions are highly variable because of segmental deletions in old NA genes. Possible mechanisms for such deletions are discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6094954

Source DB:  PubMed          Journal:  Mol Biol Med        ISSN: 0735-1313


  3 in total

1.  The major 85-kDa surface antigen of the mammalian-stage forms of Trypanosoma cruzi is a family of sialidases.

Authors:  S Kahn; T G Colbert; J C Wallace; N A Hoagland; H Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

2.  Mutations in the cytoplasmic tail of influenza A virus neuraminidase affect incorporation into virions.

Authors:  P Bilsel; M R Castrucci; Y Kawaoka
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

3.  The cytoplasmic tail of influenza A virus neuraminidase (NA) affects NA incorporation into virions, virion morphology, and virulence in mice but is not essential for virus replication.

Authors:  L J Mitnaul; M R Castrucci; K G Murti; Y Kawaoka
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.